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Abstract
Aptamers continue to receive interest as potential therapeutic agents for the treatment of diseases, including cancer. In order
to determine whether aptamers might eventually prove to be as useful as other clinical biopolymers, such as antibodies, we
selected aptamers against an important clinical target, human epidermal growth factor receptor (hEGFR). The initial selection
yielded only a single clone that could bind to hEGFR, but further mutation and optimization yielded a family of tight-binding
aptamers. One of the selected aptamers, E07,bound tightly to the wild-typereceptor (Kd=2.4 nM). This aptamer cancompete
with EGF for binding, binds to a novel epitope on EGFR, and also binds a deletion mutant, EGFRvIII, that is commonly found in
breast and lung cancers, and especially in grade IV glioblastoma multiforme, a cancer which has for the most part proved
unresponsive to current therapies. The aptamer binds to cells expressing EGFR, blocks receptor autophosphorylation, and
prevents proliferation of tumor cells in three-dimensional matrices. In short, the aptamer is a promising candidate for further
development as an anti-tumor therapeutic. In addition, Aptamer E07 is readily internalized into EGFR-expressing cells, raising
the possibility that it might be used to escort other anti-tumor or contrast agents.
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Introduction
Aptamers have been selected against a surprising range of
targets, ranging from ions to small organics to proteins to
supramolecular structures such as viruses and tissues [1], [2].
Aptamers targeting proteins in the bloodstream or on cell surfaces
have proven to be useful for therapy. For instance, aptamers have
been selected against a number of growth factors such as basic
fibroblast growth factor (bFGF) [3], vascular endothelial growth
factor (VEGF) [4], platelet-derived growth factor (PDGF) [5], and
keratinocyte growth factor (KGF) [6]. These aptamers could block
the interactions between growth factors and their receptors, and
have proven to be excellent drug candidates. An anti-VEGF
aptamer has been approved by FDA in 2004 for the treatment of
neovascular age-related macular degeneration.
Aptamers are not only useful in their own right, but as escorts
for therapeutic or diagnostic reagents. Modified RNA anti-PSMA
(prostate-specific membrane antigen) aptamers [7] have been used
by many research groups as targeting agents and conjugated to a
variety of molecules including gold nanoparticles, siRNA, and
drug encapsulated polymer particles for specific delivery [8], [9],
[10], [11], [12]. Modified RNA aptamers against the virion
surface glycoprotein, gp120 [13] were conjugated to an anti-
human immunodeficiency virus siRNA, and both the aptamer and
the siRNA portions of the chimera had potent anti-HIV activity
[14].
Aptamers targeting cell surface receptors may be amongst the
most useful for biomedical applications (reviewed in [15], [16]).
HER3 (human epidermal growth factor receptor-3) is membrane-
bound protein and is related to the development of some
malignant tumors. RNA aptamers against HER3 have shown
strong inhibitory effects on hrg (heregulin)-induced growth
stimulation of MCF7 cells [17]. Both DNA and RNA anti-mouse
transferrin receptor aptamers have been selected and used to
mediate the endocytosis of lysosomal enzymes [18]. Anti-RET
receptor tyrosine kinase aptamers have been selected against cells
expressing human RET, and one of them was found to block
RET-dependent intracellular signaling pathways. [19].
We have previously isolated a RNA aptamer targeting EGFR
and utilized it for nanoparticle delivery [20]. Here we report a 29
F-Py modified anti-EGFR aptamer that can inhibit EGF
stimulated EGFR phosphorylation and cell proliferation. This
aptamer may provide the basis for further development of anti-
tumor therapeutics.
Material and Methods
In vitro selection of anti-EGFR 29-fluoropyrimidine RNA
aptamers
The DNA library for selection consisted of a 62-nucleotide
random region (N62) flanked by two constant regions: 59-
gataatacgactcactataggcgctccgaccttagtctctg-N62-gaaccgtgtagcacagc-
aga-39 (T7 RNA polymerase promoter is underlined). The initial
RNA pool was generated by transcribing some 10
14 DNA
templates using a Durascribe kit (Epicentre, Madison, WI)
followed by DNase treatment and PAGE purification. About 2
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8nmoles RNA and 90 pmoles recombinant human EGFR-Fc
(hEGFR) fusion protein (R&D Systems, Minneapolis, MN) were
used for each round of selection in a reaction volume of 100 mL.
To prepare the substrate for selection, human EGFR-Fc protein
was immobilized to Protein G magnetic beads (New England
Biolabs, Ipswich, MA) as follows: Protein G beads (200 uL) were
first washed twice with 200 uL of DPBS (Invitrogen, Carlsbad,
CA). Beads were removed from the DPBS buffer and hEGFR
(50 mg) resuspended in 200 mL DPBS was added. The immobi-
lization reaction was incubated overnight at 4uC. Protein G beads
with or without human EGFR (hEGFR) were washed twice with
Selection Buffer (1X DPBS and 5 mM MgCl2) prior to being used
in selections.
For rounds of selection, RNA was first thermally equilibrated by
heating to 75uC for 3 minutes and cooling at 1uC/s to ambient
temperature in 100 mL of Selection Buffer, and then incubated
with 100 mL of Protein G beads. Following this negative selection,
the RNA solution was removed and incubated with the hEGFR-
conjugated protein G beads (50 mL) at 25uC for 30 min. The
human EGFR-conjugated Protein G beads were washed 3 times
with 100 mL of Selection Buffer and then heated to 95uC for 5 min
in Elution Buffer (200 mM NaCl, 25 mM EDTA, and 8 M urea)
to release any bound RNA. The eluted RNA was rinsed over M30
filters (Millipore, Bedford, MA) twice with 150 mL of water to
remove salt and urea, eluted in water, reverse transcribed, and
PCR amplified. The DNA pool from Round 10 of the selection
was cloned and sequenced according to standard procedures.
Aptamer E01 was resynthesized as a 30% doped sequence pool
as previously described [20], and used for selection. The selection
with the doped pool was carried out as above, except that RNA
was first incubated with hEGFR-conjugated Protein G beads.
Eluted RNA was purified using M30 filters and then incubated
with hIgG (human IgG, R&D Systems)-conjugated Protein G
beads at 25uC for 30 min. Human IgG-conjugated Protein G
beads were prepared as described above for hEGFR-conjugated
Protein G beads. RNA that remained in solution following this
negative selection was again purified using M30 filters, reverse
transcribed, and PCR amplified. The DNA pools from Round 7
(30 clones) and Round 9 (40 clones) were cloned and sequenced.
Binding specificities and dissociation constants
To make monomeric hEGFR, about 0.3 mg of hEGFR was
incubated in Selection Buffer with or without 5 mM DTT for
10 min at 25uC. To confirm that the monomer had been
produced the solution was mixed with 4X loading dye and loaded
onto a 4–12% NuPAGE gel (Invitrogen) with 1X MOPS running
buffer alongside marker proteins. The gel was developed at 200 V
for 1 hour, and stained as previously described (Supplementary
Material, [20]).
Aptamers E03, E04, and E07 were assayed for their ability to
bind either dimeric or monomeric hEGFR. Some 10 nM [a-
32P]-
ATP-labeled (3000Ci/mmol, 10mCi/ml, Perkin Elmer, Waltham,
MA) Aptamers E03, E04, and E07 were incubated with 100 nM
hEGFR (with or without DTT treatment) for 30 min at 25uCi n
Selection Buffer. To assess binding specificity, about 10 nM of
[a-
32P]-ATP-labeled Aptamers E03, E04, and E07 were also
incubated with 100 nM hIgG and mEGFR (mouse EGFR) with or
without DTT treatment for 30 min at 25uC in Selection Buffer.
All protein were from R&D Systems. The binding reaction was
loaded onto on a vacuum manifold (Schleicher & Schuell, Keene,
NH) with two layers of filters. The top layer was nitrocellulose and
captured only the RNA:protein complexes, while the bottom filter
was nylon and captured all remaining RNA. Sample wells were
washed three times with 300 uL of Selection Buffer, and
nitrocellulose and nylon filters were dried and visualized using a
Phosphorimager (GE Healthcare, Piscataway, NJ).
To measure dissociation constants for aptamer:protein com-
plexes, about 0.1 nM [c-
32P]-ATP-labeled Aptamers E03, E04,
and E07 were incubated with different concentrations of hEGFR
(0.1 nM, 0.3 nM, 1 nM, 3.2 nM, 10 nM, 32 nM, and 100 nM)
and mEGFR (1 nM, 3.2 nM, 10 nM, 32 nM, and 100 nM,
316 nM, and 1000 nM) for 30 min at 25uC. The binding assays
were carried out as described above, and dissociation constants
were calculated as previously describe [20].
Assaying cell surface binding of anti-EGFR aptamers
Aptamers were synthesized with a 24 nt extension at 39 end (59-
GAAUUAAAUGCCCGCCAUGACCAG-39) and hybridized to
a biotinyated DNA oligoucleotide. Phycoerythrin-labeled strep-
tavdin (SA-PE, Prozyme, San Leandro, CA) was added to the
RNA:DNA duplex without further purification [15].
A431 cells were purchased from ATCC (American type Culture
Collection, Manassas, VA) and MDA-MB-435 cells were obtained
from the laboratory of Dr. Konstantin Sokolov at University of
Texas at Austin. Both cell lines were cultured in DMEM (ATCC)
with 10% FBS (Invitrogen). Cells were grown to 70% confluence,
trypsinized, washed, and counted.
About 0.2 million cells were incubated with 100 nM labeled
pools or aptamers in 100 uL of Selection Buffer for 30 min at
25uC. Cells were then washed with 100 uL of Selection Buffer 3
times and resuspended in 300 uL of Selection Buffer. Samples
were analyzed on the FL2-H channel of a FACSCalibur (BD
Biosciences, San Jose, CA).
Competitive binding to the cell surface was assessed by mixing
Alexa Fluor 488-labeled EGF (0.1 ug/mL, ca. 1.5 nM, Invitrogen)
with either unselected N62 pool RNA pool, Aptamer E03,
Aptamer E04, or Aptamer E07 (1 uM ). The competitive binding
reactions were incubated with 0.2 million trypsinized and washed
A431 cells in 100 uL of Selection buffer at 25uC for 30 min.
Samples were washed 3 times with 100 ul of Selection Buffer,
resuspended in 300 ul of Selection Buffer, and analyzed on the
FL1-H (for Alex Fluor 488) channel of a FACSCalibur.
Tyrosine phosphorylation assay
A431 cells were seeded in a 24-well plate, grown for 24 hours in
DMEM medium with 10% FBS, and then serum-starved for
18 hours. Cells were then incubated for 20 min at 37uC with either
2n ME G F , ,2n ME G Fa n d1 0 0n MA bC 2 2 5 , ,2n ME G Fa n d
1 mM unselected N62 pool RNA,, 2 nM EGF and 1 mM Aptamer
E07,, 1 mM unselected N62 pool RNA,, or 1 mM Aptamer E07. After
removing the media, cells were lysed in 100 ml1 XR I P Ab u f f e r
(Thermo Fisher Scientific, Waltham, MA) for 5 min and further
disrupted using an ultrasonic dismembrator (Thermo Fisher Scientif-
ic). Western blot analysis was done as previously described [15]. A
biotinylated anti-phosphotyrosine antibody (4G10) (Millipore) was
used as the primary antibody and an anti-mouse IgG-AP conjugate
(Promega, Madison, WI) was used as the secondary antibody.
Internalization assay
TheinternalizationofAptamerE07wasassayedbyflowcytometry
as previously described (Supplementary Material, [20]). A negative
control (Mutant Aptamer) was generated by scrambling the sequence
derived from the random region of Aptamer E01 (http://workbench.
sdsc.edu/). Phycoerythrin-labeled Aptamer E07 and the Mutant
Aptamer were incubated with 0.2 million trypsinized and washed
A431 cells for 30 min either on ice or at 37uC in 100 uL of Selection
Buffer. The cells were then treated with 0.01 u/mL Riboshredder
(Epicentre Biotechnologies, Madison, WI) for 10 min at 25uC
A Cell Proliferation Inhibiting Anti-EGFR Aptamer
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were resuspended in 300 ul of Selection Buffer and analyzed by flow
cytometry as described above. The amount of internalized Aptamer
E07 was calculated using the following equation:
RNA Internalized~
F2{F0
F1{F0
ð1Þ
where F0, F1, and F2 represent the fluorescence of Mutant
Aptamer-labeled cells, the fluorescence of Aptamer E07-labeled
cells, and the fluorescence of Aptamer E07-labeled cells after
Riboshredder treatment, respectively.
Cell proliferation assay in 3D culture
A431 cells were trypsinized and resuspended in Matrigel (BD
Biosciences). On day 0, about 3,000 cells in 200 ul of Matrigel
were seeded in a 48-well plate and covered with 200 ul of
complete media (DMEM with 10% FBS). The media was replaced
on Days 1, 3, 5, 7, 9, and 11 with 200 ul of DMEM with 1% FBS
containing either 1 uM Mutant Aptamer, Aptamer E07, dephos-
phorylated Mutant Aptamer or dephosphorylated Aptamer E07.
On Day 13, media -was removed and the Matrigel was incubated
with 400 ul of Cell Recovery Solution (BD Biosciences) on ice for
4 hours. Samples containing A431 colonies were transferred to a
24-well plate and imaged with an IX51 Inverted Microscope
(Olympus, Center Valley, PA) under 4x objective. Released cell
colonies were lysed and the nucleic acids content was measured
using a CyQUANTH Cell Proliferation Assay Kit (Invitrogen).
Results were analyzed in Microsoft Excel with Anova analysis.
Dephosphorylated aptamers were prepared by incubating RNA
with Antarctic Phosphatase (New England Biolabs, Ipswich, MA).
Some 8 nmoles of RNA was incubated with 75 units phosphatase
in a 100 uL reaction at 37uC for 30 min. The phosphatase was
deactivated at 65uC for 5 min. RNA was purified prior to use by
ethanol precipitation.
Assaying binding of aptamer E07 to the EGFRvIII deletion
variant
To test for binding of Aptamer E07 with hEGFRvIII mutant
purified protein, 10 nM [a-
32P]-ATP-labeled Aptamer E07 was
incubated with 50 ug hEGFR (R&D Systems) and 50 ug
hEGFRvIII deletion mutant protein (gift of Dr. George Georgiou,
University of Texas at Austin), for 30 min at 25uC. The binding
assay was carried out as described above.
To test for binding of the aptamer to the deletion mutant in the
context of the cell surface, U87MG delta vIII cells were obtained
from Dr. Frank Furnani, University of California San Diego, and
were cultured in High Glucose DMEM with 10% FBS. Cells were
grown to 70% confluence, trypsinized, washed, and counted.
FACs assays for cell surface binding and internalization with
Aptamer E07 were performed as described above.
Results
Isolation of 29-fluoropyrimidine modified anti-EGFR
aptamers
We had previously isolated RNA aptamers against EGFR [20],
but now wanted to generate aptamers that would be much more
stable in vivo. We initially targeted a purified Fc-EGFR fusion
protein conjugated to Protein G beads, and initiated selections
with a 29-fluoropyrimidine modified RNA pool that spanned 62
random positions. The in vitro half life of 29-fluoropyrimidine
modified aptamers in plasma is typically several hours to days,
[21,22]which should assist with further therapeutic development of
any aptamers found. Negative selections against Protein G beads
were carried out prior to each round of positive selection. After 10
rounds of selection and amplification the percentage of bound
RNA that bound to Fc-EGFR (1 uM) increased from 2% to 39%.
Some 33 clones from the final round of selection were sequenced
(Table S1). Many of the selected sequences contained the
consensus motif 59-GGUGCU-39 which is known to bind to the
Fc portion of the fusion protein (Miyakawa, S., Y. Nomura, et al.
2008). However, one clone, Aptamer E01 (which was isolated 4 /
33 times), did not contain this motif and bound specifically to
human EGFR with a dissociation constant of about 40 nM. The
random region of Aptamer E01 was only 51 nt in length (rather
than 62 nt). This was likely due to the accumulation of a deletion
variant during PCR amplification. This aptamer was re-synthe-
sized as a doped sequence pool and the negative selection against
human IgG1 was carried out each round after (rather than before)
positive selection against human EGFR. After 9 rounds of
selection, the percentage of bound RNA that bound to Fc-EGFR
increased from 2% to 22%. The selected pool also showed some
cross-binding to the non-cognate protein Fc-ErbB2 (5%), but this
is perhaps not surprising as the original unselected N62 pool
showed very high background binding to hErbB2 (32%). This
background binding may be due to the positively charged
polyhistidine tag on hErbB2, which is not present on hEGFR.
Twenty one clones from Round 7 and 51 clones from Round 9
were sequenced (the sequences derived from the random regions
are shown in Table S2). While the wild-type aptamer was not
recovered, Aptamer E30 and E39 appeared twice, and all other
aptamer sequences appeared once.
Table 1. Sequences of isolated anti-EGFR aptamers.
Clone Sequence
E01 UGCCGCUAUAUCGCACGUAUUUAAUCGCCGUAGAAAAGCAUGUCCAAGCCG
E02 UGGCGCUAAAUAGCACGGAAAUAAUCGCCGUAGAAAAGCAUGUCAAAGCCG
E03 UGCUAGUAUAUCGCACGGAUUUAAUCGCCGUAGAAAAGCAUGUCAAAGCCG
E04 UGCCGCCAUAUCACACGGAUUUAAUCGCCGUAGAAAAGCAUGUCAAAGCCG
E05 UUCCGCUGUAUAACACGGACUUAAUCGCCGUAGUAAAGCAUGUCAAAGCCG
E06 UGUCGCUCUAUUGCACGGAUUUAAUCGCCGUAGAAAAGCAUGUCAAAGCCG
E07 UGCCGCUAUAAUGCACGGAUUUAAUCGCCGUAGAAAAGCAUGUCAAAGCCG
Only the random sequence portions of the aptamers are shown. Substitutions relative to Aptamer E01 are shown in bold italics.
doi:10.1371/journal.pone.0020299.t001
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were further screened for their ability to bind to cells expressing
EGFR. Aptamers were transcribed with a 24-nt extension,
hybridized with a biotinylated antisense oliognucleotide, and
incubated with SA-PE. Labeled aptamers were incubated with
A431 cells, and binding was analyzed by FACS. Aptamers E02-
, E03-, E04-, E05-, E06-, and E07-labeled cells showed greater
fluorescence signals than other aptamers (Table 1). Interest-
ingly, these aptamers all contained U40G and C67A mutations
which could reinforce a particular aptamer conformation
(Figure S1). When comparing the parental aptamer (E01)
and the derived aptamer E07, G40 reinforces a predicted stem,
while A67 disfavors a short stem and reinforces an internal
loop.
Figure 1. Binding specificity of anti-EGFR aptamers. The N62 pool and aptamers E03, E04, and E07 were assayed in triplicate by filtration for
binding to hEGFR, mEGFR, hErbB2, and hIgG1. Average values and standard deviations are shown. Binding assays were carried out either in the
absence (left) or presence (right) of DTT. A no protein control was also carried through the procedure. Percent binding was relative to the total RNA
added.
doi:10.1371/journal.pone.0020299.g001
Figure 2. Binding constants for Aptamers E03, E04, and E07. Binding isotherms were constructed using 0.1 nM aptamer and varying amounts
of hEGFR or mEGFR. Binding assays were carried out in triplicate and the average value and standard deviation are shown. The fact that binding does
not reach 100% is a function of the filtration assay, and is commonly observed. Dissociation constants were calculated following curve-fitting, as
described in Materials and Methods.
doi:10.1371/journal.pone.0020299.g002
A Cell Proliferation Inhibiting Anti-EGFR Aptamer
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Based on the sequencing and binding assay results, aptamer E03,
04, and E07 were chosen for further characterization. In order to
ascertain the specificity of the aptamers, binding to hEGFR,
mEGFR, hErbB2, and hIgG1 was probed. As shown in Figure 1,
these three aptamers bound to both hEGFR and mEGFR, but not
to hErbB2 nor hIgG1. The doped sequence selection therefore
eliminated the cross-binding to hErbB2 that was observed with the
original pool. Cross-binding between the human and mouse forms
of the protein is perhaps not surprising because these two proteins
show 88% identity in their amino acid sequences. A filter-binding
assay was used to generate binding isotherms and the dissociation
constants of Aptamers E03, E04, and E07werefound to be 2–3 nM
with hEGFR and 30–50 nM with mEGFR (Figure 2). The
aptamers bound almost as tightly to EGFR as the natural ligand
EGF and the therapeutic mAb C225 (both at ca. 1 nM) [23].
Since the selection was carried out against a dimeric form of the
protein (dimerization was through disulfide bond formation in the
Fcfusion, and thismaybe be verydifferentfrom thedimerfound on
the cell surface), we attempted to determine whether the aptamers
could specifically recognize the EGFR dimer. DTT was added to
reduce the disulfide bonds and generate an EGFR monomer fusion
protein; the formation of monomers was confirmed by native gel
electrophoresis asshown previously [20].As shown inFigure 1, the
addition of DTT to the binding buffer does not affect the binding
affinity of Aptamer E03, E04, and E07.
Anti-EGFR aptamers bind to cells expressing EGFR
Due to the potential conformational differences between purified
proteins and those that reside on cell surfaces, aptamers isolated
against purified proteins do not always bind to cells [24]. Therefore,
aptamers were assayed for their ability to bind to both A431
epidermoid carcinoma cells (1–3 million EGFR molecules per cell)
and MDA-MB-435 breast cancer cells (EGFR deficient). These cell
lines had previously been used to detect the cellular binding of a
previously selected anti-EGFR RNA aptamer (J18) [20].
Aptamers E03, E04, and E07 were all found to bind A431 cells
but the unselected N62 pool RNA did not (Figure 3A). None of
the aptamers bound above background to the negative control cell
line, MDA-MB-435 (Figure 3B). Thus, the aptamers appear to
be capable of recognizing monomer EGFR in the context of the
cell surface. As was the case with the protein in vitro, the addition of
DTT did not impact binding to cells.
Aptamer E07 blocks EGF binding to EGFR and inhibits
EGF-stimulated EGFR phosphorylation
EGF binds to EGFR, and stimulates its dimerization,
phosphorylation, and downstream signaling. Efficiently blocking
the interaction between EGF and EGFR could inhibit cell
proliferation and tumor growth. Using labeled EGF and FACS
as an assay, aptamers E03, E04, and E07 were found to block
binding of EGF to A431 cells, while the unselected N62 pool RNA
did not (Figure 3C). Western blot analyses also show that
Aptamer E07 blocked EGF-induced EGFR phosphorylation
(Figure 4A). Different concentrations of Aptamer E07 were used
to inhibit EGFR phosphorylation and the inhibition constant was
found to be approximately 300 nM (Figure 4B). The significant
difference between the observed dissociation constant of Aptamer
E07 with EGFR and its apparent inhibition constant for
phosphorylation inhibition is likely due to the fact that the binding
constant was measured against purified protein while the
inhibition constant was determined via a cell-based assay.
Figure 3. Cellular binding and inhibition of EGF-binding by anti-EGFR aptamers. Phycoerythrin-labeled N62 pool (green line), Aptamer E03
(pink line), Aptamer E04 (cyan line), and Aptamer E07 (orange line) were incubated with EGFR-overexpressing cells (A431); (A) and EGFR-negative cells
(MDA-MB-435); (B) and analyzed on the FL2-H channel of a FACSCalibur. A no RNA control was also carried out. Alexa 488-labeled EGF (0.1 ug/ml, ca.
1.5 nM) was incubated with A431 cells (green line), and binding assessed by FACS. The interaction could be blocked by the further addition of 1 uM
Aptamer E03 (cyan line), Aptamer E04 (orange line) and Aptamer E07 (dark blue line) but not unselected N62 pool RNA (pink line)(C). Counts
represent number of cells counted.
doi:10.1371/journal.pone.0020299.g003
A Cell Proliferation Inhibiting Anti-EGFR Aptamer
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Receptor-mediated endocytosis is a process by which cells
uptake molecules, including cytokines such as EGFR, from their
surroundings. We have previously developed a flow cytometry-
based assay to monitor the internalization of aptamers that bind to
receptors on the cell surface [15]. In short, aptamer:PE complexes
are added to cells either at 37uC (where internalization is active) or
4uC (where internalization is dormant). After allowing the
aptamers to internalize, the cell surfaces are challenged with
nucleases. Only those aptamers that have been internalized
remain and can be detected by FACS. As a control for
internalization, a Mutant Aptamer was designed by scrambling
the random region of Aptamer E07.
Aptamer E07 and Mutant Aptamer were assayed for
internalization. Mutant Aptamer does not bind to A431 cells at
either temperature. Riboshredder completely removed Aptamer
E07 from A431 cells that were incubated on ice (left, Figure 5),
but about 23% Aptamer E07 was resistant to Riboshredder
(right, Figure 5)a t3 7 uC, presumably because it had been
internalized.
Figure 4. Aptamer inhibition of EGFR phosphorylation. The phosphorylation of EGFR was stimulated by 2 nM EGF and was detected by
Western blot analysis using an anti-tyrosine phosphorylation antibody, (A, lane 2). The additions to individual reactions are shown above the gel
lanes. Arrows show the position of proteins. Staining was also carried out with an anti-beta-actin antibody to ensure that similar amounts of samples
were loaded. Phosphorylation is inhibited by the addition of 100 nM Ab C225 (A, lane 3), 1 uM Aptamer E07 (A, lane 4), but not unselected N62 pool
RNA (A, lane 5). Aptamer 07 and pool RNA alone do not induce EGFR phosphorylation (A, lanes 6 and 7). The approximate inhibition constant for
Aptamer E07 is about 300 nM (B).
doi:10.1371/journal.pone.0020299.g004
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We evaluated the ability of Aptamer E07 to inhibit A431 cell
proliferation. Because culturing cells on flat plasticware results in
artificial, two-dimensional sheets of cells, we have grown A431
cells in three-dimensional environments that better mimic their in
vivo counterparts. To avoid the potential interferon induction by
the triphosphate group at the 59 end of the RNA [25], both
Aptamer E07 and Mutant Aptamer were first treated with
phosphatase. Dephosphorylation did not impact the binding of
E07 to cells (Figure S2). A431 cells were treated with Aptamer
E07 and Mutant Aptamer every other day for 6 total treatments.
The size of the A431 colonies treated with both Aptamer E07 and
dephosphorylated Aptamer E07 decreased greatly (Figure 6A).
Because cell DNA content for individual cells is constant, the
amount of DNA measured by the fluorescence intensity correlates
with cell number, therefore cell proliferation. The number of A431
cells in the observed colonies decreased about 80% when treated
with Aptamer E07 and dephosphorylated Aptamer E07. In
contrast, the number of cells decreased about 30% when treated
with Mutant Aptamer or dephosphorylated Mutant aptamer.
(p=5.4E213) (Figure 6B). Despite aptamer dephosphorylation,
the decreased fluorescence signal of Mutant Aptamer treated cells
could be due to non-specific inhibitory effects, such as the
activation of innate immune responses, as has been observed with
structured siRNAs [26,27].
Discussion
The four members of the epidermal growth factor receptor
family have proven to be excellent targets for cancer therapy [28].
Aptamers against EGFR members may therefore prove to be
excellent therapeutic candidates. Anti- Her3 aptamers have been
isolated and have been shown to inhibit heregulin signaling [17].
However, these anti-Her3 aptamers did not contain any
modifications and were nuclease sensitive, and thus their in vivo
application was greatly limited. We have previously isolated an
anti-EGFR RNA aptamer [20], that was similarly labile. Nuclease
degradation of aptamers can be slowed from a half life of only a
few minutes to hours by incorporating modified nucleoside
triphosphates into selections [29]. Our selections with 29-
fluoropyrimidines yielded a relatively small number of nuclease-
stable aptamers that appeared to be capable of binding the
monomer. The extracellular domain of EGFR contains four
subdomains, I, II, III, and IV, with subdomains II and IV being
cysteine-rich and therefore also known as CR1 and CR2 [30].
Since binding of the aptamer to both the protein in vitro and to cells
was insensitive to DTT, we can hypothesize that the epitope
bound by the aptamer was distinct from the cysteine-rich
subdomains II and IV of the protein, because these contain a
number of disulfide bonds. Similarly, the crystal structure and
other biochemical results show that domains I and III are involved
in EGF binding [31]. Because Aptamer E07 successfully competed
with EGF for binding to EGFR, we further hypothesize that the
binding site for Aptamer E07 should at least partially overlap the
EGF binding site on domains I and III.
We also attempted to determine whether Aptamer E07 could
bind to the common EGFR deletion variant, EGFRvIII in which
residues 6–273 from domain I (residues 1–165) and II (residues
166–310) are removed. The aptamer showed significant binding
relative to no protein controls (Figure S3 A). It is therefore
possible that Aptamer E07’s major binding site on EGFR resides
on domain III. Given these promising results, we then assayed
whether the aptamer bound to a cell line (U87MG delta vIII) that
had been engineered to overexpress the variant EGFRvIII
(although this line also still displays low levels of wild-type EGFR
[32,33]). Strong binding and internalization was observed (Figure
S3 B), indicating that the aptamer can recognize the deletion
variant and may promote internalization of this receptor.
Figure 5. Internalization of anti-EGFR Aptamer E07. Phycoerythrin-labeled unselected N62 pool RNA (100 nM, green line) and PE-labeled
Aptamer E07 (100 nM, cyan line) were incubated with A431 cells either on ice (left) or at 37uC (right) for 30 min. After the binding reaction, cells were
exposed to Riboshredder for 10 min at 25uC (pink line and orange lines, respectively). Residual fluorescence was analyzed by FACS. Putative
internalized Aptamer E07 conjugates are indicated by arrows. Counts represent number of cells counted.
doi:10.1371/journal.pone.0020299.g005
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with the ability of the aptamer to inhibit EGFR function. EGFR is
known to be present on the surface of cells in two conformations:
an inactive conformation where domain II and IV are tethered,
and subdomains I and III are held too far apart for EGF to bind
both domains simultaneously, and an active conformation in
which domain I becomes available for ligand cobinding with
domain III. It has been postulated that about 3–15% of the
unstimulated receptor is in the active form at any time, and that
EGF binding drives the conformational equilibrium toward the
active state [34]. In the active state the dimerization arm of
domain II is released from its tether, allowing the protein to homo-
or heterodimerize. Subsequent activation of EGFR’s intrinsic
protein tyrosine kinase activity occurs and leads to autophospho-
rylation of tyrosine residues in the C-terminal domain. Autophos-
phorylation in turn triggers a complex intracellular signal
transduction pathway involving the Ras-Raf-MAP-kinase cascade,
PI3K (phosphatidyl inositol 3-kinase), the downstream protein
kinase Akt, and various transcription factors such as STAT (signal
transducer and activator of transcription) [35], [36]. These
signaling proteins modulate phenotypes such as cell migration,
adhesion, invasion, cell proliferation, angiogenesis, and resistance
to apoptosis [36]. As a result, EGFR has been shown to be a tumor
biomarker [37], and there are a number of already approved anti-
EGFR pharmaceuticals with more in clinical trials.
While therapeutic aptamers are virtually unknown at the current
time, therapeutic antibodies are widespread [38]. Because of the
importance of EGFR in oncogenesis, anti-EGFR antibodies have
been developed as therapeutics. A mouse monoclonal anti-EGFR
antibody (clone 225) binds to EGFR with affinity similar to EGF
(1nM), blocks EGF-induced activation of EGFR tyrosine phos-
phorylation, and induces internalization of EGFR without stimu-
lating EGFR phosphorylation [39]. To reduce the immunogenicity
of mouse antibody C225, a chimera consisting of its murine Fv
region and human IgG1 heavy and kappa light chain regions has
been developed [23]. The chimeric anti-EGFR antibody, also
known as Cetuximab, was approved by the FDA for the treatment
of colorectal cancer and head and neck cancer in 2004. Other anti-
EGFR antibodies that are in clinical use and that have similar
(thought not identical) mechanisms of action include Panitumumab.
Despite the fact that Cetuximab and other antibodies have
proven to be clinically useful, they do possess some disadvantages.
There are numerous side-effects from treatment with anti-EGFR
antibodies, including immunogenic responses such as skin
(acneiform rash) and other toxicities that may stem directly from
anti-EGFR activity [40], and anaphylactic or allergic reactions
[41]. Early trials with head and neck squamous cell carcinomas
had to be canceled because of adverse effects, including several
deaths. Similar problems were observed during the treatment of
non-small-cell lung cancers [42].
Figure6. Inhibition ofA431 cell proliferation by Aptamer E07. A431 cells were seeded intoMatrigel in 48 well plates andtreated with untreated
or dephosphorylatedAptamer E07 orMutantAptamer (1 uM) everyotherdayfora totalof6 treatments.(A)Cell colonieswerereleasedfromMatrigelby
Cell Recovery Solution, transferred to a 24-well plate, andimaged with anIX51Inverted Microscope (Olympus, Center Valley, PA) under4x objective. The
inset shows which of the five micrographs go with which specific treatment parameters. (B) The nucleic acids content was measured using a CyQUANTH
Cell Proliferation Assay Kit. CyQUANTH GR dye was incubated with cell lysate and exhibited strong green fluorescence when bound to cellular nucleic
acids. The fluorescence is linearly correlated with the number of cells and readily detected by a plate reader. (p=5.4E213).
doi:10.1371/journal.pone.0020299.g006
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resistant to anti-EGFR antibodies [43]. Cetuximab and other
many other anti-EGFR antibodies block dimerization [44].
Resistance can arise because of mutations that favor the
overexpression of EGFR, the ‘untethered’ conformation, and /
or ligand-independent activation [45], [46]. Further, there are
reports that there is wide variation in the efficacy of Cetuximab for
treating cell lines and cancers that express EGFRvIII [47,48].
Anti-EGFR aptamers are likely to have lower immunogenicity
(and hence potentially lower toxicity) than antibodies, and will
interact differently with EGFR than antibodies, potentially
increasing efficacy and overcoming resistance to antibody
therapeutics.
Our anti-EGFR aptamers may also prove useful as escorts for
other therapies. Aptamers have previously been used to escort
toxins [49], small organic drugs [50], and even siRNA molecules
[8], [11], [51] into cells. Upon binding, both EGF and Cetuximab
induce EGFR internalization (although the mechanism of
antibody-induced internalization remains unclear) [52]. The
internalization of
125I-EGF and
125I-225 mAb has been compared
in A549 lung adenocarcinoma cells [53], and within approxi-
mately 15 min, the internal-to-surface ratio was found to plateau
at values of 2.5 for
125I-EGF and 0.4 for
125I-225 mAb. While we
are still exploring the mechanism of the anti-EGFR aptamer
internalization, we have found there is about 22% of Aptamer E07
internalized into A431 cells within 30 min. This value translates to
an internal-to-surface ratio of 0.3, comparable to that found with
125I-225 mAb (0.4). We can now explore whether E07 can be
further improved by acting as a cytotoxic delivery reagent,
including to cells expressing the EGFRvIII deletion variant.
Supporting Information
Figure S1 Predicted secondary structure of Aptamer
E01 and Aptamer E07. Secondary structures were predicted
using the program MFOLD. The sequence substitutions U40G
and C67A were highlighted in red in Aptamer E07.
(TIF)
Figure S2 Impact of dephosphorylation on aptamer
inhibition of EGF-binding. Alexa 488-labeled EGF (0.1 ug/
ml, ca. 1.5 nM) was incubated with A431 cells (green line), and
binding assessed by FACS. The interaction could be blocked by
1 uM Aptamer E07 (cyan line) and dephosphorylated Aptamer
E07 (dark blue line), but not by a Mutant Aptamer (pink line) or
the dephosphorylated Mutant Aptamer (orange line). Counts
represent number of cells counted.
(TIF)
Figure S3 Binding and internalization of anti-EGFR
Aptamer E07 in cells expressing the EGFRvIII deletion
variant (A) and binding of E07 Aptamer to the EGFRvIII
deletion variant protein (B). (A) Phycoerythrin-labeled
Aptamer E07 (100 nM, cyan line) was incubated with U87MG
delta vIII cells at 37uC for 30 min. After the binding reaction, cells
were exposed to Riboshredder for 10 min at 25uC (pink and
orange lines, respectively). Residual fluorescence was analyzed by
FACS. Counts represent number of cells counted. (B) Binding was
measured were using 0.1 nM aptamer and 50 ug of hEGFR or
hEGFRvIII. Binding assays were carried out in triplicate and the
average values and standard deviations are shown.
(TIF)
Table S1 Sequences of anti-EGFR aptamers isolated from the
N62 pool. Only the random sequence portions of the aptamers are
shown. The known Fc-binding motif GGUGCU was highlighted
in red. N represents an undetermined nucleotide. The number of
times the aptamer was isolated is shown on the right.
(XLS)
Table S2 Sequences of anti-EGFR aptamers isolated from a
doped Aptamer E01 pool. Only the random sequence portions of
the aptamers are shown. Aptamer E30 and E39 (red) appeared
twice. N represents an undetermined nucleotide.
(XLS)
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